Niagen Bioscience (NAGE) Gross Profit (2010 - 2026)

Niagen Bioscience (NAGE) has reported Gross Profit for 17 consecutive years, with $20.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit rose 3.34% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $83.8 million (up 24.27% YoY), while the FY2025 annual figure was $83.2 million, up 35.08% from the prior year.
• Gross Profit retreated to $20.0 million in Q1 2026 per NAGE's latest filing, from $21.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $21.9 million in Q3 2025 and bottomed at $10.0 million in Q2 2022.
• Historically, Gross Profit has averaged $15.2 million across 5 years, with a median of $13.5 million in 2023.
• Annual changes were most pronounced in 2022 — Gross Profit declined 7.1% — and 2025, when it soared 47.71%.
• Niagen Bioscience's Gross Profit stood at $12.0 million in 2022, then grew by 7.66% to $12.9 million in 2023, then jumped by 40.66% to $18.2 million in 2024, then gained by 19.27% to $21.7 million in 2025, then slipped by 7.96% to $20.0 million in 2026.
• Business Quant data shows NAGE's Gross Profit at $20.0 million in Q1 2026, $21.7 million in Q4 2025, and $21.9 million in Q3 2025.